A Metal-Free Method for Producing MRI Contrast at Amyloid-β

Silvia Hilt, Tang Tang, Jeffrey H. Walton, Madhu Budamagunta, Izumi Maezawa, Tamás Kálai, K. Hideg, Vikrant Singh, Heike Wulff, Qizhi Gong, Lee Way Jin, Angelique Louie, John C. Voss

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is characterized by depositions of the amyloid-β (Aβ) peptide in the brain. The disease process develops over decades, with substantial neurological loss occurring before a clinical diagnosis of dementia can be rendered. It is therefore imperative to develop methods that permit early detection and monitoring of disease progression. In addition, the multifactorial pathogenesis of AD has identified several potential avenues for AD intervention. Thus, evaluation of therapeutic candidates over lengthy trial periods also demands a practical, noninvasive method for measuring Aβ in the brain. Magnetic resonance imaging (MRI) is the obvious choice for such measurements, but contrast enhancement for Aβ has only been achieved using Gd(III)-based agents. There is great interest in gadolinium-free methods to image the brain. In this study, we provide the first demonstration that a nitroxide-based small-molecule produces MRI contrast in brain specimens with elevated levels of Aβ. The molecule is comprised of a fluorene (a molecule with high affinity for Aβ) and a nitroxide spin label (a paramagnetic MRI contrast species). Labeling of brain specimens with the spin-labeled fluorene produces negative contrast in samples from AD model mice whereas no negative contrast is seen in specimens harvested from wild-type mice. Injection of spin-labeled fluorene into live mice resulted in good brain penetration, with the compound able to generate contrast 24-h post injection. These results provide a proof of concept method that can be used for early, noninvasive, gadolinium-free detection of amyloid plaques by MRI.

Original languageEnglish
Pages (from-to)1667-1681
Number of pages15
JournalJournal of Alzheimer's Disease
Volume55
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Amyloid
Metals
Magnetic Resonance Imaging
Alzheimer Disease
Brain
Gadolinium
Spin Labels
Injections
Amyloid Plaques
Electron Spin Resonance Spectroscopy
Dementia
Disease Progression
Early Diagnosis
Peptides
fluorene

Keywords

  • Alzheimer's disease
  • amyloid MRI contrast
  • amyloid-β
  • magnetic resonance imaging
  • nitroxide spin label
  • spin-labeled fluorene

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Hilt, S., Tang, T., Walton, J. H., Budamagunta, M., Maezawa, I., Kálai, T., ... Voss, J. C. (2017). A Metal-Free Method for Producing MRI Contrast at Amyloid-β. Journal of Alzheimer's Disease, 55(4), 1667-1681. https://doi.org/10.3233/JAD-160279

A Metal-Free Method for Producing MRI Contrast at Amyloid-β. / Hilt, Silvia; Tang, Tang; Walton, Jeffrey H.; Budamagunta, Madhu; Maezawa, Izumi; Kálai, Tamás; Hideg, K.; Singh, Vikrant; Wulff, Heike; Gong, Qizhi; Jin, Lee Way; Louie, Angelique; Voss, John C.

In: Journal of Alzheimer's Disease, Vol. 55, No. 4, 2017, p. 1667-1681.

Research output: Contribution to journalArticle

Hilt, S, Tang, T, Walton, JH, Budamagunta, M, Maezawa, I, Kálai, T, Hideg, K, Singh, V, Wulff, H, Gong, Q, Jin, LW, Louie, A & Voss, JC 2017, 'A Metal-Free Method for Producing MRI Contrast at Amyloid-β', Journal of Alzheimer's Disease, vol. 55, no. 4, pp. 1667-1681. https://doi.org/10.3233/JAD-160279
Hilt S, Tang T, Walton JH, Budamagunta M, Maezawa I, Kálai T et al. A Metal-Free Method for Producing MRI Contrast at Amyloid-β. Journal of Alzheimer's Disease. 2017;55(4):1667-1681. https://doi.org/10.3233/JAD-160279
Hilt, Silvia ; Tang, Tang ; Walton, Jeffrey H. ; Budamagunta, Madhu ; Maezawa, Izumi ; Kálai, Tamás ; Hideg, K. ; Singh, Vikrant ; Wulff, Heike ; Gong, Qizhi ; Jin, Lee Way ; Louie, Angelique ; Voss, John C. / A Metal-Free Method for Producing MRI Contrast at Amyloid-β. In: Journal of Alzheimer's Disease. 2017 ; Vol. 55, No. 4. pp. 1667-1681.
@article{454aaba1e6bc4f0e9434a55e9e64b947,
title = "A Metal-Free Method for Producing MRI Contrast at Amyloid-β",
abstract = "Alzheimer's disease (AD) is characterized by depositions of the amyloid-β (Aβ) peptide in the brain. The disease process develops over decades, with substantial neurological loss occurring before a clinical diagnosis of dementia can be rendered. It is therefore imperative to develop methods that permit early detection and monitoring of disease progression. In addition, the multifactorial pathogenesis of AD has identified several potential avenues for AD intervention. Thus, evaluation of therapeutic candidates over lengthy trial periods also demands a practical, noninvasive method for measuring Aβ in the brain. Magnetic resonance imaging (MRI) is the obvious choice for such measurements, but contrast enhancement for Aβ has only been achieved using Gd(III)-based agents. There is great interest in gadolinium-free methods to image the brain. In this study, we provide the first demonstration that a nitroxide-based small-molecule produces MRI contrast in brain specimens with elevated levels of Aβ. The molecule is comprised of a fluorene (a molecule with high affinity for Aβ) and a nitroxide spin label (a paramagnetic MRI contrast species). Labeling of brain specimens with the spin-labeled fluorene produces negative contrast in samples from AD model mice whereas no negative contrast is seen in specimens harvested from wild-type mice. Injection of spin-labeled fluorene into live mice resulted in good brain penetration, with the compound able to generate contrast 24-h post injection. These results provide a proof of concept method that can be used for early, noninvasive, gadolinium-free detection of amyloid plaques by MRI.",
keywords = "Alzheimer's disease, amyloid MRI contrast, amyloid-β, magnetic resonance imaging, nitroxide spin label, spin-labeled fluorene",
author = "Silvia Hilt and Tang Tang and Walton, {Jeffrey H.} and Madhu Budamagunta and Izumi Maezawa and Tam{\'a}s K{\'a}lai and K. Hideg and Vikrant Singh and Heike Wulff and Qizhi Gong and Jin, {Lee Way} and Angelique Louie and Voss, {John C.}",
year = "2017",
doi = "10.3233/JAD-160279",
language = "English",
volume = "55",
pages = "1667--1681",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - A Metal-Free Method for Producing MRI Contrast at Amyloid-β

AU - Hilt, Silvia

AU - Tang, Tang

AU - Walton, Jeffrey H.

AU - Budamagunta, Madhu

AU - Maezawa, Izumi

AU - Kálai, Tamás

AU - Hideg, K.

AU - Singh, Vikrant

AU - Wulff, Heike

AU - Gong, Qizhi

AU - Jin, Lee Way

AU - Louie, Angelique

AU - Voss, John C.

PY - 2017

Y1 - 2017

N2 - Alzheimer's disease (AD) is characterized by depositions of the amyloid-β (Aβ) peptide in the brain. The disease process develops over decades, with substantial neurological loss occurring before a clinical diagnosis of dementia can be rendered. It is therefore imperative to develop methods that permit early detection and monitoring of disease progression. In addition, the multifactorial pathogenesis of AD has identified several potential avenues for AD intervention. Thus, evaluation of therapeutic candidates over lengthy trial periods also demands a practical, noninvasive method for measuring Aβ in the brain. Magnetic resonance imaging (MRI) is the obvious choice for such measurements, but contrast enhancement for Aβ has only been achieved using Gd(III)-based agents. There is great interest in gadolinium-free methods to image the brain. In this study, we provide the first demonstration that a nitroxide-based small-molecule produces MRI contrast in brain specimens with elevated levels of Aβ. The molecule is comprised of a fluorene (a molecule with high affinity for Aβ) and a nitroxide spin label (a paramagnetic MRI contrast species). Labeling of brain specimens with the spin-labeled fluorene produces negative contrast in samples from AD model mice whereas no negative contrast is seen in specimens harvested from wild-type mice. Injection of spin-labeled fluorene into live mice resulted in good brain penetration, with the compound able to generate contrast 24-h post injection. These results provide a proof of concept method that can be used for early, noninvasive, gadolinium-free detection of amyloid plaques by MRI.

AB - Alzheimer's disease (AD) is characterized by depositions of the amyloid-β (Aβ) peptide in the brain. The disease process develops over decades, with substantial neurological loss occurring before a clinical diagnosis of dementia can be rendered. It is therefore imperative to develop methods that permit early detection and monitoring of disease progression. In addition, the multifactorial pathogenesis of AD has identified several potential avenues for AD intervention. Thus, evaluation of therapeutic candidates over lengthy trial periods also demands a practical, noninvasive method for measuring Aβ in the brain. Magnetic resonance imaging (MRI) is the obvious choice for such measurements, but contrast enhancement for Aβ has only been achieved using Gd(III)-based agents. There is great interest in gadolinium-free methods to image the brain. In this study, we provide the first demonstration that a nitroxide-based small-molecule produces MRI contrast in brain specimens with elevated levels of Aβ. The molecule is comprised of a fluorene (a molecule with high affinity for Aβ) and a nitroxide spin label (a paramagnetic MRI contrast species). Labeling of brain specimens with the spin-labeled fluorene produces negative contrast in samples from AD model mice whereas no negative contrast is seen in specimens harvested from wild-type mice. Injection of spin-labeled fluorene into live mice resulted in good brain penetration, with the compound able to generate contrast 24-h post injection. These results provide a proof of concept method that can be used for early, noninvasive, gadolinium-free detection of amyloid plaques by MRI.

KW - Alzheimer's disease

KW - amyloid MRI contrast

KW - amyloid-β

KW - magnetic resonance imaging

KW - nitroxide spin label

KW - spin-labeled fluorene

UR - http://www.scopus.com/inward/record.url?scp=85007188991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007188991&partnerID=8YFLogxK

U2 - 10.3233/JAD-160279

DO - 10.3233/JAD-160279

M3 - Article

C2 - 27911291

AN - SCOPUS:85007188991

VL - 55

SP - 1667

EP - 1681

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -